Condition (MeSH)
Pseudohypoaldosteronism
ClinicalTrials.gov lists 12 trials for Pseudohypoaldosteronism or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Pseudohypoaldosteronism itself; the rest are tagged with a narrower condition beneath it.
When did Pseudohypoaldosteronism trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2022 | 3 |
| 2018 | 1 |
| 2010 | 1 |
| 2009 | 1 |
| 2008 | 1 |
| 2006 | 2 |
| 1997 | 1 |
| 1992 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pseudohypoaldosteronism trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Observational | 10 |
How many Pseudohypoaldosteronism trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 7 |
| Terminated | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pseudohypoaldosteronism trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
Which drugs are being tested for Pseudohypoaldosteronism? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sodium polystyrene sulfonate | 1 |
| Enalapril | 1 |
Interventions as named in the registry (1)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Lokelma Oral Product | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Pseudohypoaldosteronism? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cardiovascular effects of aldosterone: insight from adult carriers of mineralocorticoid receptor mutations. | Circulation. Cardiovascular genetics | 2013 | Yes |
| Cyclosporine metabolic side effects: association with the WNK4 system. | European journal of clinical investigation | 2011 | Yes |
| Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. | Human mutation | 2007 | Yes |
| Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. | Kidney international | 2008 | No |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Pseudohypoaldosteronism | 444916 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Pseudohypoaldosteronism | 444916 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and sub-conditions in mesh.